Affimed to Report 3rd Quarter 2020 Financial Results & Corporate Update November 10, 2020
November 03 2020 - 6:30AM
Heidelberg, Germany, November 3, 2020 – Affimed
N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company
committed to giving patients back their innate ability to fight
cancer, announced today that it will release third quarter 2020
results on Tuesday, November 10, 2020 and host a conference call at
8:30 a.m. ET to discuss financial results and corporate
developments.
The conference call will be available via phone and webcast. To
access the call, please dial +1-646-741-3167 for U.S. callers, or
+44 (0) 2071 928338 for international callers, and reference
conference ID 9847055 approximately 15 minutes prior to the
call.
To access the live audio webcast of the conference call please
visit the “Investors” section of the company’s website at
https://www.affimed.com/investors/webcasts_cp/. A replay of the
call will be archived on the Affimed website for 30 days after the
call.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology
company committed to giving patients back their innate ability to
fight cancer. Affimed’s fit-for-purpose ROCK® platform allows
innate cell engagers to be designed for specific patient
populations. The company is developing single and combination
therapies to treat hematologic and solid tumors. The company is
currently enrolling patients into a registration-directed study of
AFM13 for CD30-positive relapsed/refractory peripheral T cell
lymphoma and into a Phase 1/2a dose escalation/expansion study of
AFM24 for the treatment of advanced EGFR-expressing solid tumors.
For more information, please visit www.affimed.com.
Investor Relations Contact
Alex FudukidisHead of Investor RelationsE-Mail:
a.fudukidis@affimed.comTel: +1 (917) 436-8102
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024